Blog

Key takeaways from EMBARK by Bertrand Tombal

Bertrand Tombal/medimix.be

Nov 30, 2024, 19:17

Key takeaways from EMBARK by Bertrand Tombal

Dra. María Natalia Gandur Quiroga, Coordinator in charge of the Urology Clinic Service at the Angel H. Roffo Institute, shared a post on X:

“Amazing session by Bertrand Tombal at PROSCA24. Key takeaways from EMBARK.

EMBARK redefines BCR: Adding enzalutamide + ADT significantly improves metastasis-free survival (MFS) and overall survival (OS).
Patient benefits: Enzalutamide monotherapy shows significant MFS improvement over ADT alone, paving the way for its role as systemic therapy.
AE Profile: Combination of enzalutamide and ADT increases grade ≥3 adverse events (31.3%) but remains manageable.
High-risk outcomes: Patients with PSA doubling ≤9 months benefit most.
Post hoc insights: Sexual activity-related quality of life remains comparable with delayed TTCD in enzalutamide monotherapy.

Is it still acceptable to delay enzalutamide initiation in EMBARK patients?”

EMBARK

For more updates, follow OncoDaily.

Angel H. Roffo Institute Bertrand Tombal cancer Dra.María Natalia Gandur Quiroga EMBARK Enzalutamide monotherapy OncoDaily Oncology Patient benefits PROSCA24 systemic therapy

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Richard Sullivan: The State of Global Cancer Surgery from Political and Equity Perspectives

Immunotherapy for Bladder Cancer: Types, Success Rate, Side Effects & More

Radiotherapy for Anus Cancer: Types, Success Rate, Side Effects And More

Special Coverage